Voxalatamab

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer[1][2].

Product Specifications

CAS Number

[2411871-58-2]

Product Name Alternative

JNJ-63898081; JNJ-081

UNSPSC

12352203

Target

CD3; PSMA

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/voxalatamab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Voxalatamab]

Molecular Weight

(144.68 kDa)

References & Citations

[1]Jonas S Heitmann, et al. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers (Basel) . 2021 Feb 1;13 (3) :549.|[2]Lim EA, et al. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023 Jun;21 (3) :366-375.